Unplanned medication discontinuation as a potential pharmacovigilance signal: A nested young person cohort study

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Sun, Angela Peichen ^a   Kirby, Bradley ^a   Black, Corri ^a   Helms, Peter John ^a   Bennie, Marion ^b   McLay, James Stuart ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

^c ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adverse drug reaction; Child; Computerized; Medical records systems; Obesity; Orlistat; Pharmacoepidemiology; Pharmacovigilance; Young people

Indexed keywords

TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; LACTONE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; COHORT ANALYSIS; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HUMAN; INFANT; INFECTION; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PRESCRIPTION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SYMPTOM; TREATMENT DURATION; UNPLANNED MEDICATION DISCONTINUATION; URINARY TRACT DISEASE; URINE RETENTION; UROGENITAL TRACT DISEASE; CLINICAL PRACTICE; FACTUAL DATABASE; MEDICATION COMPLIANCE; NEWBORN; PRESCHOOL CHILD; PRIMARY HEALTH CARE; STATISTICS;

ADOLESCENT; ANTI-OBESITY AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LACTONES; MALE; MEDICATION ADHERENCE; PHARMACOVIGILANCE; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE;

EID: 84902530324     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-11     Document Type: Article

References (63)

1. Turner S, Nunn AJ, Fielding K, Choonara I: Adverse drug reactions to unlicensed and off-label drugs on paediatric wards. Acta Paediatr 1999, 88(9):965-968
2. Horen B, Montastruc JL, Lapeyre-Mestre M: Adverse drug reactions and offlabel drug use in paediatric outpatients. Br J Clin Pharmacol 2002, 54:665-670
3. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M: Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001, 52(1):77-83
4. Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P: Adverse drug reactions in children-a systematic review. PLOS One 2012. DOI: 10.1371/journal.pone.0024061
5. Jonville-Bera AP, Giraudeau B, Blanc P, Beau-Salinas F, Autret-Leca E: Frequency of adverse drug reactions in children: a prospective study. Br J Clin Pharmacol 2002, 53(2):207-210
6. Whyte J, Greenan E: Drug usage and adverse drug reactions in paediatric populations. Acta Paediatr Scand 1977, 66(6):767-775
7. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ: A prospective study of adverse drug reactions in hospitalised children. Br J Clin Pharmacol 1999, 47(6):681-688
8. Weiss J, Krebs S, Hoffman C, Werner U, Neubert A, Brune K, Rascher W: Survey of adverse drug reactions on a paediatric ward: a strategy for early and detailed detection. Pediatrics 2002, 110(2 Pt 1):254-257
9. Kramer MS, Hutchinson TA, Flegel KM, Naimark L, Contardi R, Leduc DG: Adverse drug reactions in general paediatric outpatients. J Paediatr 1985, 106(2):305-310
10. Davies EC, Green CF, Mottram DR, Pirmohamed M: Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharmacol Ther 2006, 31:335-341
11. Martin RM, Kapoor KV, Wilton LV, Mann RD: Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998, 317:119-120
12. Reporting adverse drug reactions. A guide for healthcare professionals. 2006 BMA Board of Science. British Medical Association, BMA House, Tavistock Square, London, WC1H 9JP. http://www.isoponline.org/documents/news/BMAreport.pdf. © British Medical Association
13. Smith CC, Bennet PM, Pearce HM, Harrison HI, Reynolds DJM, Aronson JK, Graeme-Smith DG: Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on the Safety of Medicines. Brit J Clin Pharmacol 1996, 42:423-9
14. Schirm E, Tobil H, Van Puijenbroek EP, Monster-Simons MH, den Berg LTW DJ-V: Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmacoepi Drug Safety 2004, 13:159-65
15. Hawcutt DB, Pramod M, Riordan A, Smyth R, Pirmohamed M: Reported paediatric adverse drug reactions in the UK 2000-2009. Brit JClin Pharmacol 2012, 73:437-446. Doi: 10.1111/j.1365-2125.2011.04113.x
16. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell J, Krska L, Lee AD, McLernon DJ, Murphy E, Shakir S, Watson MJ: Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme: literature review, descriptive and qualitative analyses and questionnaire surveys. Health Technol Assess 2011, 15(20):33-47
17. Broyles S, Katzmarzyk PT, Srinivasan SR, Chen W, Bouchard C, Freedman DS, Berenson GS: The pediatric obesity epidemic continues unabated in Bogalusa, Louisiana. Pediatr 2010, 125(5):900-905
18. Wang Y, Monteiro C, Popkin BM: Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. Am J Clin Nutr 2002, 75(6):971-977
19. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006, 26(5):968-976. 20
20. Must A: Morbidity and mortality associated with elevated body weight in children and adolescents. Am J Clin Nutr 1996, 63(3 Suppl):445S-447S
21. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety 2008, 31(1):53-65
22. Acharya NV, Wilton LV, Shakir SA: Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes 2006, 30(11):1645-1652. 23: Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, Fernandez ML. Orlistatinduced cutaneous leukocytoclastic vasculitis. Arthritis & Rheumatism 2002 Oct 15;47(5):567
23. Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, Fernandez ML. Orlistatinduced cutaneous leukocytoclastic vasculitis. Arthritis & Rheumatism 2002 Oct 15;47(5):567
24. Sergeant A, Milne G, Shaffrali F: Lichenoid eruption associated with orlistat. Br J Dermatol 2006, 154(5):1020-1021
25. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA: Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002, 10(7):642-650
26. Ozkan B, Bereket A, Turan S, Keskin S: Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004, 12(163(12)):738-741
27. Norgren S, Danielsson P, Jurold R, Ltborn M, Marcus C: Orlistat treatment in obese prepubertal children: a pilot study. Acta Pædiatr 2003, 92(6):666-70
28. Mohamed IN, Helms PJ, Simpson CR, Milne RM, McLay JS: Using primary care prescribing databases for pharmacovigilance. Br J Clin Pharmacol 2011, 71(2):244-249
29. Mohamed IN, Helms PJ, Simpson CR, McLay JS: Using primary care prescribing databases for pharmacovigilance. Brit J Clin Pharmacol 2011, 712:244-249
30. Scottish Index of Multiple Deprivation. http://www.scotland.gov.uk/Topics/Statistics/SIMD Accessed 01 04 2013
31. Read Code User Guide Dr. Lesley Graham, Ann Ward, Gerry Mulvenna. ISD Scotland July 2000. https://www.google.co.uk/search?q=Read+Code+User+Guide+Dr.+Lesley+Graham,+Ann+Ward,+Gerry+Mulvenna.+599+ISD+Scotland+July+2000.&ie=utf-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefoxa&channel=sb&gws_rd=cr&ei=SakZU8iFLaWS7AaIiYA4 Accessed 23/07/2013)
32. Database review by PCCIU. http://www.abdn.ac.uk/iahs/uploads/files/PCI. pdf. Accessed 25 06 2013
33. Whitelaw FG, Nevin SL, Milne RM, Taylor RJ, Taylor MW, Watt AH: Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. B J G P 1996, 46(404):181-186
34. Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK, 1990. Arch Dis Child 1995, 73(1):25-29
35. British National Formulary, Volume No 64. BMJ and Pharmaceutical Press; 2012 ISBN 978 0 85711 065 7
36. Mohamed IN, Helms PJ, Simpson CR, McLay JS: Using routinely collected prescribing data to determine drug persistence for the purpose of pharmacovigilance. J Clin Pharmacol 2011, 51(2):279-284
37. Viner RM, Hsia Y, Neubert A, Wong ICK: Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol 2009, 68(6):844-851
38. Tebbi CK: Treatment compliance in childhood and adolescence. Cancer 1993, 71(10 Suppl):3441-3449
39. Friedman IM, Litt IF: Adolescents' compliance with therapeutic regimens. Psychological and social aspects and intervention. J Adolescent Health Care 1987, 8(1):52-67
40. Tebbi CK, Cummings KM, Zevon MA: Compliance of pediatric and adolescent cancer patients. Cancer 1986, 58(5):1179-1184
41. Tucker CM, Fennell RS, Pedersen T, Higley BP, Wallack CE, Peterson S: Associations with medication adherence among ethnically different pediatric patients with renal transplants. Pediatr Nephrol 2002, 17(4):251-256
42. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23(8):1296-1310
43. Kinra S, Nelder RP, Lewendon GJ: Deprivation and childhood obesity: a cross sectional study of 20,973 children in Plymouth, United Kingdom. J Epidemiol Community Health 2000, 54(6):456-460
44. Strauss RS, Knight J: Influence of the home environment on the development of obesity in children. Pediatr 1999, 103(6):e85
45. Goldblatt PB, Moore ME, Stunkard AJ: Social factors in obesity. JAMA 1965, 192:1039-1044
46. Sobal J, Stunkard AJ: Socioeconomic status and obesity: a review of the literature. Psychol Bull 1989, 105(2):260-275
47. Yanovski JA, KrakoffJ, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA: Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011, 60(2):477-485
48. Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S: Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008, 9(6):567-576
49. Atabek ME, Pirgon O: Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebocontrolled clinical trial. J Pediatr Endocrinol 2008, 21(4):339-348
50. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell CT: Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clinl Endocrinol Metab 2006, 91(6):2074-2080
51. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatr 2001, 107(4):E55
52. Love-Osborne K, Sheeder J, Zeitler P: Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008, 152(6):817-822
53. Murray ML, de Vries CS, Wong IC: A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 2004, 89(12):1098-1102
54. Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, Dubowski M, Mendez-Lewis M: Psychotropic medication patterns among youth in foster care. Pediatr 2008, 121(1):e157-63
55. Mustillo S, Worthman C, Erkanli A, Keeler G, Angold A, Costello EJ: Obesity and psychiatric disorder: developmental trajectories. Pediatr 2003, 111(4 Pt 1):851-859
56. Atlantis E, Baker M: Obesity effects on depression: systematic review of epidemiological studies. Int J Obes 2008, 32(6):881-891
57. Revah-Levy A, Speranza M, Barry C, Hassler C, Gasquet I, Moro MR, Falissard B: Association between Body Mass Index and depression: the "fat and jolly" hypothesis for adolescents girls. BMC Public Health 2011, 11:649
58. Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J: Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293(23):2873-83
59. Singh A, Sarkar SR, Gaber LW, Perazella MA: Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007, 49(1):153-157
60. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, Wald R, Amit MPH, Garg X: Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011, 171(7):703-4
61. MHRA orlistat drug analysis print. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/index.htm?secLevelIndexChar=Oq%20-%20Ou#retainDisplay Accessed 22.01.2014
62. Highlights of prescribing information-Xenical. http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/020766s029lbl.pdf Accessed 19/06/2013)
63. The World Health Organisation: Pharmacovigilance toolkit. pharmacovigilance methods. http://www.pvtoolkit.org/index.php?option=com_content&view=article&id=6&Itemid=10 Accessed 20. 07 2013